Diamonds and Dogs


Drug and biotech stocks acting better. Bristol (BMY) is up 1.5% continuing momentum from the merger with Celgene. Kodiak Science (KOD) is jumping 62% after taking in $225 million for selling royalty rights to one of their promising drugs. Clovis Oncology (CLVS) is up 10% on M&A speculation.

Tech taking it on the chin. The tech sector is down 1.6% led by interactive software firm, Roku (ROKU). Roku is down 15% on a downgrade from Morgan Stanley. After rising five-fold since the start of the year, the analyst at Morgan Stanley said its time to take profits, anticipating slower growth in active users and advertising. The new price target is $110 a share or 18% higher than current levels.

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.